Jordi Monés

TL;DR: Because photodynamic therapy with verteporfin can safely increase the chance of stabilizing or improving vision in patients with subfoveal CNV from pathologic myopia compared with a placebo, it is recommended ophthalmologists consider vertEPorfin therapy for treatment of such patients.

TL;DR: Ground-breaking innovations in diagnostic technologies, such as optical coherence tomography, allows unprecedented high-resolution visualisation of disease morphology and provides a promising horizon for early disease detection and efficient therapeutic follow-up, but definite conclusions from morphologic parameters are still lacking, and valid biomarkers have yet to be identified to provide a practical base for disease management.

TL;DR: A classification system and criteria for OCT-defined atrophy in the setting of AMD has been proposed based on an international consensus and is a more complete representation of changes that occur in AMD than can be detected using color fundus photography alone.

TL;DR: Although the primary outcome was not statistically significantly in favor of verteporfin therapy at 2 years as it had been at 1 year of follow-up, the distribution of change in visual acuity at the month 24 examination showed that this group was more likely to have improvedVisual acuity through the month24 examination.

TL;DR: The study group suggests that the consensus standards outlined in this article be used in future reported studies of neovascular AMD and clinical practice.